Zacks Investment Research
17 Mar 2026, 14:55 UTC · 31w ago
Impact · against what's priced in
The report identifies a significant gap between vTv Therapeutics' current price and analyst price targets, alongside positive earnings revisions. This suggests fundamental momentum that is not yet fully reflected in the stock's valuation.
No priced-in read yet
What the story claims
2 claims · scored −1 bearish … +1 bullish
Wall Street analysts have a mean short-term price target of $53.33 for vTv Therapeutics (VTVT), representing a potential 39.9% upside from its recent close of $38.13.
So whatA significant gap between current price and consensus analyst targets typically attracts bullish momentum and buying interest.
More positive than 81% of claims this week
There is strong agreement among analysts regarding positive revisions to vTv Therapeutics' earnings estimates.
Continue reading
5 related stories
Wall Street analysts see a 39.9% upside potential with a mean price target of $53.33 compared to the current price of $38.13, supported by strong agreement on positive earnings revisions.
Read from the article alone
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 69% of claims this week
Which stocks this story touches
More positive than 90% of ticker scores this week
The stock has gained 12.6% recently and analysts suggest significant upside potential with an average price target of $53.33.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
6h ago
−27.0%
Price is moving against the score
$27.84 vs $38.13 close before publication (Mar 16) · not market-adjusted
VTVT chart →
